Physician profile
Michael D Reep
NPI 1578544284
$308,179.40
in general payments reported to CMS, 2019-2025
43 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $26K · 2021: $41K · 2022: $45K · 2023: $81K · 2024: $34K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $117K · Food and Beverage: $18K · Travel and Lodging: $2,024 · Consulting Fee: $1,500 · Education: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $117,450.00 |
| Food and Beverage | $17,552.45 |
| Travel and Lodging | $2,023.62 |
| Consulting Fee | $1,500.00 |
| Education | $529.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $113,695.16 | 2019-2025 | Otezla, Otezla, Enbrel |
| Galderma Laboratories, L.P. | $67,568.20 | 2019-2025 | Aklief, Epsolay, Oracea |
| Celgene Corporation | $26,009.23 | 2019 | |
| Dermavant Sciences, INC. | $24,692.44 | 2022-2024 | Vtama |
| Incyte Corporation | $23,575.59 | 2021-2025 | Opzelura |
| Dermira, INC. | $14,454.62 | 2019-2021 | |
| Journey Medical Corporation | $7,851.43 | 2019-2025 | |
| Pfizer INC. | $7,196.88 | 2019-2023 | |
| Abbvie INC. | $3,025.79 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $2,661.48 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Aclaris Therapeutics, INC. | $2,614.17 | 2019 | |
| Janssen Biotech, INC. | $2,289.46 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $1,724.60 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $1,397.28 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $1,207.62 | 2019-2025 | Dupixent, Libtayo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $996.76 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Novartis Pharmaceuticals Corporation | $967.70 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $908.54 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Ucb, INC. | $818.55 | 2019-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $739.29 | 2019-2025 | |
| Genzyme Corporation | $701.60 | 2019-2025 | |
| Promius Pharma LLC | $531.63 | 2019 | |
| Arcutis Biotherapeutics, INC. | $485.49 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.90 | 2022-2025 | Spevigo, Cyltezo |
| Organon LLC | $338.31 | 2025 | Vtama, Nexplanon |
| Verrica Pharmaceuticals INC. | $266.16 | 2023-2024 | Ycanth |
| Almirall LLC | $224.64 | 2019-2022 | |
| Epi Health, LLC | $151.12 | 2019-2022 | |
| Genentech USA, INC. | $148.61 | 2019-2025 | Xolair |
| Vyne Pharmaceuticals INC. | $109.66 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2019 | |
| Prugen, INC. Pharmaceuticals | $56.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.71 | 2019 | |
| Mylan Institutional INC. | $41.47 | 2023 | Hulio |
| Biofrontera INC. | $35.40 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Medimetriks Pharmaceuticals, INC. | $33.48 | 2019-2025 | Clindacin Etz |
| Taro Pharmaceuticals USA, INC. | $25.82 | 2019 | |
| Kyowa Kirin, INC. | $21.77 | 2024 | Poteligeo |
| Mylan Pharmaceuticals INC. | $16.95 | 2019 | |
| Fresenius Kabi USA, LLC | $16.82 | 2023 | |
| Lnhc, INC | $15.41 | 2025 | Zelsuvmi |
| Revance Therapeutics, INC. | $15.19 | 2024 | Daxxify |
| Encore Dermatology INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Reep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.